Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
267 hedge funds and large institutions have $3.41B invested in Apellis Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 96 increasing their positions, 94 reducing their positions, and 39 closing their positions.
209% more call options, than puts
Call options by funds: $128M | Put options by funds: $41.5M
21% more capital inflows, than outflows
Capital inflows: $558M | Capital outflows: $460M
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
15% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 39
1.94% more ownership
Funds ownership: 95.11% → 97.05% (+1.9%)
2% more funds holding
Funds holding: 263 → 267 (+4)
2% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 94
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Braidwell
Stamford,
Connecticut
|
+$93.1M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
+$70.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$52.2M |
| 4 |
Morgan Stanley
New York
|
+$47.1M |
| 5 |
JP Morgan Chase
New York
|
+$26.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$65.6M |
| 2 |
AG
Artal Group
Luxembourg
|
-$56.3M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$39.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.3M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.4M |
APLS Hedge Fund Activity: Q3 2024 in Review
267 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2024, worth a combined $3.41B — down 23% from $4.43B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new APLS positions and 39 closed out — a net gain of 6 holders — while 96 added to existing stakes and 94 trimmed.
The largest buyer was Braidwell, adding an estimated $93.1M. The largest seller was Jennison Associates, cutting an estimated $65.6M.
- 267 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2024, up from 263 in Q2 2024.
- Funds reported $3.41B of Apellis Pharmaceuticals stock for Q3 2024, down 23% quarter-over-quarter.
- 45 funds opened new Apellis Pharmaceuticals positions in Q3 2024 and 39 closed out, a net change of +6 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2024 was Braidwell, an estimated $93.1M added.
- The largest Apellis Pharmaceuticals seller in Q3 2024 was Jennison Associates, an estimated $65.6M sold.
Based on aggregated 13F filings for Q3 2024.